Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06333860 · ClinicalTrials.gov registry record · Phase 4
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
A Phase 4 study of Moderate Plaque Psoriasis, sponsored by AbbVie.
- Active
- Registry status
- Phase 4
- Development phase
- 393
- Enrollment target
- 20
- Study locations
NCT06333860 is a Phase 4 study of Moderate Plaque Psoriasis that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 393 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT06333860, a Phase 4 study of Moderate Plaque Psoriasis, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 393 participants
- Enrollment target
- 20
- Study locations
Study Summary
Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not working properly. This study is designed to enroll 336 participants 18 years of age and older with have been diagnosed with moderate chronic plaque psoriasis for at least 6 months prior to Baseline (Day 1) and who have not previously been treated with a biologic treatment (natural substance that is made by using living cells in a laboratory). This is a Phase 4, randomized, open-label, assessor blinded, active comparator study with 2 Parts. Phase 4 studies test treatments that have already been approved to treat patients with a condition or disease. This study is open-label, which means that both participants and study doctors know which study treatment is given to participants Participants will be administered subcutaneous (SC) treatment of risankizumab every 12 weeks for up to 44 weeks or provided deucravacitinib oral tablets to be taken once daily. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Risankizumab
- DRUG Deucravacitinib
Study Locations (20)
Florida
- Clearlyderm Dermatology - West Boca /ID# 264963 - Boca Raton
- Driven Research /ID# 263002 - Coral Gables
- Skin Care Research - Hollywood /ID# 263877 - Hollywood
- International Dermatology Research /ID# 264911 - Miami
- Lenus Research and Medical Group /ID# 263886 - Miami
- Wellness Clinical Research - Miami Lakes /ID# 263887 - Miami Lakes
- Skin Care Research - Tampa /ID# 263880 - Tampa
- Advanced Clinical Research Institute /ID# 263878 - Tampa
California
- First OC Dermatology /ID# 263003 - Fountain Valley
- Integrative Skin Science and Research /ID# 264504 - Sacramento
- Physioseq, LLC /ID# 265035 - Sacramento
- Medderm Associates Dermatology /ID# 263858 - San Diego
- Southern California Dermatology /ID# 263021 - Santa Ana
Arizona
- Advanced Research Associates - Glendale /ID# 263621 - Glendale
- Clear Dermatology & Aesthetics Center /ID# 263626 - Scottsdale
Illinois
- University Dermatology and Vein Clinic, LLC /ID# 263028 - Chicago
- Arlington Dermatology /ID# 263001 - Rolling Meadows
Alabama
- Total Skin and Beauty Dermatology Center /ID# 263011 - Birmingham
Arkansas
- Dermatology Trial Associates /ID# 264480 - Bryant
Indiana
- Dawes Fretzin, LLC /ID# 264578 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2024-05-10 |
| Est. Completion | 2026-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06333860
The ClinicalTrials.gov registry entry for NCT06333860 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Risankizumab is the first listed.
NCT06333860 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06333860 about?
NCT06333860 is a clinical study titled "A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)". Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with s...
What is the current status of trial NCT06333860?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 393 participants. The study started on 2024-05-10. Estimated completion is 2026-03.
What conditions does trial NCT06333860 study?
This clinical trial studies the following conditions: Moderate Plaque Psoriasis.
What interventions are being tested in trial NCT06333860?
The interventions under investigation include: Risankizumab (DRUG), Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT06333860?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06333860 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.